The next steps and updated guidelines for the use of MRD concepts in multiple myeloma
What’s next for inotuzumab ozogamicin in ALL?
Highlights from the International Workshop of the German CLL Study Group
Results of Phase III POLLUX trial on daratumumab in multiple myeloma
New additions: novel agents to boost treatment of multiple myeloma